<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To present a case of <z:hpo ids='HP_0011009'>acute</z:hpo> mesenteric and portal vein <z:mp ids='MP_0005048'>thrombosis</z:mp> treated with thrombolytic therapy in a patient with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> in <z:hpo ids='HP_0011009'>acute</z:hpo> phase and to review the literature on thrombolytic therapy of mesenteric-portal system </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> portal vein <z:mp ids='MP_0005048'>thrombosis</z:mp> has ranged from conservative treatment with thrombolysis and anticoagulation therapy to surgical treatment with thrombectomy and/or intestinal resection </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We treated our patient with intraportal infusion of plasminogen activator and then <z:chebi fb="5" ids="28304">heparin</z:chebi> through a percutaneous transhepatic catheter </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> resolved despite premature interruption of the thrombolytic treatment for neurological complications, which subsequently resolved </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Conservative management with plasminogen activator, could be considered as a good treatment for patients with <z:hpo ids='HP_0011009'>acute</z:hpo> porto-mesenteric <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>